Covaxin's US approval delayed as FDA asks for more data

Ocugen Inc said on Thursday it would no longer pursue an emergency use authorization for its Covid-19 vaccine candidate, Covaxin, and would instead aim to file for a full US approval of the shot. Ocugen said the decision was based on a recommendation from the US Food and Drug Administration (FDA), which also requested more information and data for full approval.